BioNTech SE Sponsored ADR $BNTX Stock Bought by Candriam S.C.A.

Candriam S.C.A. grew its position in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 4.7% in the third quarter, Holdings Channel reports. The institutional investor owned 520,972 shares of the company’s stock after buying an additional 23,442 shares during the period. Candriam S.C.A.’s holdings in BioNTech were worth $51,399,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in the company. Flossbach Von Storch SE purchased a new stake in shares of BioNTech in the second quarter valued at about $207,142,000. Bank of America Corp DE increased its stake in shares of BioNTech by 22.6% during the first quarter. Bank of America Corp DE now owns 903,029 shares of the company’s stock worth $80,261,000 after acquiring an additional 166,432 shares during the period. First Trust Advisors LP increased its stake in shares of BioNTech by 116.0% during the first quarter. First Trust Advisors LP now owns 839,991 shares of the company’s stock worth $74,658,000 after acquiring an additional 451,124 shares during the period. Assenagon Asset Management S.A. raised its holdings in BioNTech by 79.7% during the third quarter. Assenagon Asset Management S.A. now owns 760,675 shares of the company’s stock worth $74,774,000 after purchasing an additional 337,412 shares in the last quarter. Finally, Pictet Asset Management Holding SA raised its holdings in BioNTech by 11.2% during the third quarter. Pictet Asset Management Holding SA now owns 206,580 shares of the company’s stock worth $20,363,000 after purchasing an additional 20,777 shares in the last quarter. Institutional investors and hedge funds own 15.52% of the company’s stock.

Insider Activity at BioNTech

In related news, CEO Ugur Sahin sold 36,209 shares of the business’s stock in a transaction dated Friday, October 9th. The shares were sold at an average price of $95.37, for a total transaction of $3,453,252.33. Following the sale, the chief executive officer owned 36,209 shares of the company’s stock, valued at approximately $3,453,252.33. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 807,209 shares of company stock valued at $79,246,837 in the last ninety days. 19.20% of the stock is owned by company insiders.

BioNTech Stock Performance

NASDAQ:BNTX opened at $87.51 on Friday. The company has a quick ratio of 7.80, a current ratio of 8.55 and a debt-to-equity ratio of 0.01. BioNTech SE Sponsored ADR has a fifty-two week low of $79.52 and a fifty-two week high of $124.00. The stock has a market cap of $22.13 billion, a PE ratio of -12.78 and a beta of 1.28. The firm’s fifty day simple moving average is $94.66 and its 200-day simple moving average is $96.70.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. Argus started coverage on shares of BioNTech in a research report on Thursday, October 8th. They issued a “hold” rating for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioNTech in a research report on Friday, October 2nd. Canaccord Genuity Group cut their target price on BioNTech from $136.00 to $132.00 and set a “buy” rating for the company in a research note on Wednesday, October 14th. Wall Street Zen raised BioNTech from a “sell” rating to a “hold” rating in a report on Saturday. Finally, Bank of America reissued a “buy” rating on shares of BioNTech in a report on Wednesday. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $123.60.

About BioNTech

BioNTech SE is a biotechnology company based in Mainz, Germany. Founded in 2008, it develops medicines and vaccines, with a focus on immunotherapies for cancer and infectious diseases.

The company’s research uses technologies including messenger RNA (mRNA), antibodies, and cell-based therapies. Its best-known product is Comirnaty, an mRNA vaccine against COVID-19 developed and commercialized in partnership with Pfizer. BioNTech also has a broad oncology research and development portfolio.

BioNTech works with partners to develop and distribute products internationally.